Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Cytochrome P450 1A2 (human) polyclonal antibody

BML-CR3130-0025 25 µl 113.00 USD
BML-CR3130-0100 100 µl 422.00 USD
Do you need bulk/larger quantities?

Product Specification

Alternative Name:CYP1A2
Immunogen:Synthetic peptide corresponding to the internal domain (aa 284-298) of human CYP1A2.
UniProt ID:P05177
Species reactivity:Human
Specificity:Recognizes human CYP1A1. Not suitable for use on rat tissue.
Applications:IHC (FS), IHC (PS), WB
Blocking Peptide:For Blocking peptide see Prod. No. BML-CP0123.
Formulation:Liquid. Serum containing 0.01% sodium azide.
Shipping:Shipped on Blue Ice
Long Term Storage:-20°C
Scientific Background:Members of the cytochrome P-450 1A (CYP1A) sub-family are induced by a range of polycyclic aromatic compounds such as benzpyrene, 3-methylcholanthrene (Prod. No. BML-GR239), and pro-carcinogenic heterocyclic aromatic amines. Cigarette smoking has been reported to induce CYP1A2 in human liver, and appears to be a major catalyst in the hepatic activation of PhIP, (2-amino-1-methyl-6-phenylimidazo[4,5,b]-pyridine). The mono-oxygenase inhibitor inhibitor enoxacin induces CYP1A2 in rat liver, whereas a related compound ciprofloxacin does not.

Related Products


Ah receptor ligand
56-49-5, ≥97% (TLC) | Print as PDF
BML-GR239-0010 10 mg 71.00 USD
BML-GR239-0050 50 mg 291.00 USD
Do you need bulk/larger quantities?

Blocking peptide for Cytochrome P450 1A2 (human) pAb (Prod. No. BML-CR3130) 

≥95% | Print as PDF
BML-CP0123-0100 100 µg 59.00 USD
Do you need bulk/larger quantities?

Product Toolbox


Certificate of Analysis


By target:
Cytochrome P450
By biological activity:
Cytochrome P450 Polyclonal antibody
By catalog section:


Technical Service
Customer Service

Related Literature

Predictive Toxicology
Predictive Toxicology
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2020 Enzo Life Sciences, Inc.,